Ovid therapeutics Inc (OVID)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.80+0.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OVID
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress OV4071, the oral KCC2 direct activator, through Phase 1 study and initiate ketamine challenge study in H2 2026 to characterize pharmacodynamics and support Phase 2 in schizophrenia and other…
Stated as a priority in 2 of last 2 quarters. OV4071 progressed with first participant dosed in Phase 1 study in 2026-Q1 and continued advancement in 2026-Q2 with plans for a ketamine challenge study in second half of 2026. Management is delivering on clinical milestones as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“OV4071 advancing in Phase 1 study; ketamine challenge study planned in second half of 2026.”
“Dosed first participant with OV4071 in Phase 1 study; ketamine challenge study planned for H2 2026.”
Continue clinical development of OV329 with Phase 2 dose-confirmatory and proof-of-concept studies in treatment-resistant focal onset seizures, TSC-associated seizures, and infantile spasms.
Stated as a priority in 2 of last 2 quarters. OV329 Phase 2 studies initiated in treatment-resistant focal onset seizures with additional pediatric studies planned for TSC and infantile spasms in late 2026 and 2027. Management is delivering clinical progress consistent with stated plans.
“Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329; plans for TSC and IS studies.”
“Advancing OV329 Phase 2 dose-confirmatory and proof-of-concept studies; planning TSC and IS pediatric programs.”
Ensure sufficient capital resources through financings and cash management to support operating plan and clinical pipeline into 2029.
Stated as a priority in 3 of last 3 quarters. Cash and marketable securities increased from $90.4 million at 2025-Q4 to $169.8 million at 2026-Q2, supported by private placements and warrant exercises. Management is delivering a strong financial runway consistent with stated capital allocation goals.
“Cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026; expected financial runway into 2029.”
“Expect to be well capitalized into 2029, with $165.6 million cash as of March 31, 2026 plus warrant proceeds.”
“Capital expected to fund operating plan and clinical pipeline into 2H 2028.”
Enhance executive leadership with new appointments to drive business development, R&D strategy, and corporate growth.
Newly stated in 2026-Q2. Management announced multiple key leadership appointments including Chief Business Officer and Executive R&D Advisor to support next phase of development. This is a recent strategic priority with initial execution.
“Strengthened executive leadership team with new appointments including Chief Business Officer and Executive R&D Advisor.”
Submit regulatory application and start Phase 1/1b clinical studies for OV4071 in 2026-Q2 as planned.
Over the trailing year it converted 0.97x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
12 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.